: Kazia Therapeutics started at buy with $18 stock price target at Maxim Group

: Kazia Therapeutics started at buy with $18 stock price target at Maxim Group

: Kazia Therapeutics started at buy with $18 stock price target at Maxim Group

Kazia Therapeutics Ltd. ADR

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.